The clinical-stage precision oncology company completed its 31.4 million-share public offering at $17.50 each, with underwriters taking all additional shares available under a 30-day option.
Erasca, Inc. said it closed its upsized underwritten public offering of 31,428,572 common shares priced at $17.50 each for expected gross proceeds of about $550.0 million before discounts, commissions, and expenses, and that the underwriters fully exercised their 30-day option to purchase up to 4,714,285 additional shares. The company had previously said the offering was expected to close on July 15, 2026, subject to customary conditions. Erasca plans to use the net proceeds, together with existing cash, cash equivalents, and marketable securities, to fund research and development for its product candidates and other development programs, as well as working capital and general corporate purposes.